Brian R Lane1, Sevag Demirjian2, Ithaar H Derweesh3, Toshio Takagi2, Zhiling Zhang4, Lily Velet2, Cesar E Ercole2, Amr F Fergany2, Steven C Campbell5. 1. Division of Urology, Spectrum Health, Michigan State University, Grand Rapids, MI, USA. 2. Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA. 3. University of California San Diego, San Diego, CA, USA. 4. Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA; Department of Urology, Sun Yat-Sen University Cancer Center, Guangzhou, China. 5. Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA. Electronic address: campbes3@ccf.org.
Abstract
BACKGROUND: Chronic kidney disease (CKD) can be associated with a higher risk of progression to end-stage renal disease and mortality, but the etiology of nephron loss may modify this. Previous studies suggested that CKD primarily due to surgical removal of nephrons (CKD-S) may be more stable and associated with better survival than CKD due to medical causes (CKD-M). OBJECTIVE: We addressed limitations of our previous work with comprehensive control for confounding factors, differentiation of non-renal cancer-related mortality, and longer follow-up for more discriminatory assessment of the impact of CKD-S. DESIGN, SETTING, AND PARTICIPANTS: From 1999 to 2008, 4299 patients underwent surgery for renal cancer at a single institution. The median follow-up was 9.4 yr (7.3-11.0). The new baseline glomerular filtration rate (GFR) was defined as the highest GFR between the nadir and 42 d after surgery. Three cohorts were retrospectively evaluated: no CKD (new baseline GFR >60 ml/min/1.73 m(2)); CKD-S (new baseline GFR<60 but preoperative >60 ml/min/1.73 m(2)); and CKD-M/S (new baseline and preoperative GFR both <60 ml/min/1.73 m(2)). Cohort status was permanently set at 42 d after surgery. INTERVENTION: Renal surgery. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Decline in renal function (50% reduction in GFR or dialysis), all-cause mortality, and non-renal cancer mortality were examined using a multivariable Cox proportional hazards model. RESULTS AND LIMITATIONS: CKD-M/S had a higher incidence of relevant comorbidities and the new baseline GFR was lower. On multivariable analysis (controlling for age, gender, race, diabetes, hypertension, and cardiac disease), CKD-M/S had higher rates of progressive decline in renal function, all-cause mortality, and non-renal cancer mortality when compared to CKD-S and no CKD (hazard ratio [HR] 1.69-2.33, all p<0.05). All-cause mortality was modestly higher for CKD-S than for no CKD (HR 1.19, p=0.030), but renal stability and non-renal cancer mortality were similar for these groups. New baseline GFR of <45 ml/min/1.73 m(2) significantly predicted adverse outcomes. The main limitation is the retrospective design. CONCLUSIONS: CKD-S is more stable than CKD-M/S and has better survival, approximating that for no CKD. However, if the new baseline GFR is <45 ml/min/1.73 m(2), the risks of functional decline and mortality increase. These findings may influence counseling for patients with localized renal cell carcinoma and higher oncologic potential when a normal contralateral kidney is present. PATIENT SUMMARY: Survival is better for surgically induced chronic kidney disease (CKD) than for medically induced CKD, particularly if the postoperative glomerular filtration rate is ≥45 ml/min/1.73 m(2). Patients with preexisting CKD are at risk of a significant decline in kidney function after surgery, and kidney-preserving treatment should be strongly considered in such cases.
BACKGROUND:Chronic kidney disease (CKD) can be associated with a higher risk of progression to end-stage renal disease and mortality, but the etiology of nephron loss may modify this. Previous studies suggested that CKD primarily due to surgical removal of nephrons (CKD-S) may be more stable and associated with better survival than CKD due to medical causes (CKD-M). OBJECTIVE: We addressed limitations of our previous work with comprehensive control for confounding factors, differentiation of non-renal cancer-related mortality, and longer follow-up for more discriminatory assessment of the impact of CKD-S. DESIGN, SETTING, AND PARTICIPANTS: From 1999 to 2008, 4299 patients underwent surgery for renal cancer at a single institution. The median follow-up was 9.4 yr (7.3-11.0). The new baseline glomerular filtration rate (GFR) was defined as the highest GFR between the nadir and 42 d after surgery. Three cohorts were retrospectively evaluated: no CKD (new baseline GFR >60 ml/min/1.73 m(2)); CKD-S (new baseline GFR<60 but preoperative >60 ml/min/1.73 m(2)); and CKD-M/S (new baseline and preoperative GFR both <60 ml/min/1.73 m(2)). Cohort status was permanently set at 42 d after surgery. INTERVENTION: Renal surgery. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Decline in renal function (50% reduction in GFR or dialysis), all-cause mortality, and non-renal cancer mortality were examined using a multivariable Cox proportional hazards model. RESULTS AND LIMITATIONS: CKD-M/S had a higher incidence of relevant comorbidities and the new baseline GFR was lower. On multivariable analysis (controlling for age, gender, race, diabetes, hypertension, and cardiac disease), CKD-M/S had higher rates of progressive decline in renal function, all-cause mortality, and non-renal cancer mortality when compared to CKD-S and no CKD (hazard ratio [HR] 1.69-2.33, all p<0.05). All-cause mortality was modestly higher for CKD-S than for no CKD (HR 1.19, p=0.030), but renal stability and non-renal cancer mortality were similar for these groups. New baseline GFR of <45 ml/min/1.73 m(2) significantly predicted adverse outcomes. The main limitation is the retrospective design. CONCLUSIONS: CKD-S is more stable than CKD-M/S and has better survival, approximating that for no CKD. However, if the new baseline GFR is <45 ml/min/1.73 m(2), the risks of functional decline and mortality increase. These findings may influence counseling for patients with localized renal cell carcinoma and higher oncologic potential when a normal contralateral kidney is present. PATIENT SUMMARY: Survival is better for surgically induced chronic kidney disease (CKD) than for medically induced CKD, particularly if the postoperative glomerular filtration rate is ≥45 ml/min/1.73 m(2). Patients with preexisting CKD are at risk of a significant decline in kidney function after surgery, and kidney-preserving treatment should be strongly considered in such cases.
Authors: Robert J Ellis; Daniel P Edey; Sharon J Del Vecchio; Megan McStea; Scott B Campbell; Carmel M Hawley; David W Johnson; Christudas Morais; Susan J Jordan; Ross S Francis; Simon T Wood; Glenda C Gobe Journal: Clin J Am Soc Nephrol Date: 2018-09-28 Impact factor: 8.237
Authors: Zachary A Hamilton; Robert G Uzzo; Alessandro Larcher; Brian R Lane; Benjamin Ristau; Umberto Capitanio; Stephen Ryan; Sumi Dey; Andres Correa; Madhumitha Reddy; James A Proudfoot; Ryan Nasseri; Kendrick Yim; Sabrina Noyes; Ahmet Bindayi; Francesco Montorsi; Ithaar H Derweesh Journal: World J Urol Date: 2018-03-12 Impact factor: 4.226
Authors: Andrew G McIntosh; Daniel C Parker; Brian L Egleston; Robert G Uzzo; Mohammed Haseebuddin; Shreyas S Joshi; Rosalia Viterbo; Richard E Greenberg; David Y T Chen; Marc C Smaldone; Alexander Kutikov Journal: BJU Int Date: 2019-06-30 Impact factor: 5.588
Authors: Bimal Bhindi; Dennis Asante; Megan E Branda; LaTonya J Hickson; Ross J Mason; Molly M Jeffery; Stephen A Boorjian; Bradley C Leibovich; R Houston Thompson Journal: Can Urol Assoc J Date: 2019-09-27 Impact factor: 1.862
Authors: Ridwan Alam; Hiten D Patel; Tijani Osumah; Arnav Srivastava; Michael A Gorin; Michael H Johnson; Bruce J Trock; Peter Chang; Andrew A Wagner; James M McKiernan; Mohamad E Allaf; Phillip M Pierorazio Journal: BJU Int Date: 2018-08-09 Impact factor: 5.588
Authors: Robert J Ellis; Sharon J Del Vecchio; Benjamin Kalma; Keng Lim Ng; Christudas Morais; Ross S Francis; Glenda C Gobe; Rebekah Ferris; Simon T Wood Journal: Int Urol Nephrol Date: 2018-06-05 Impact factor: 2.370